{"id":"NCT00506883","sponsor":"Takeda","briefTitle":"MPC-004 for the Treatment of an Acute Gout Flare","officialTitle":"A Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group, 1 Week, Dose Comparison Study to Evaluate the Efficacy, Safety, and Tolerability of MPC-004 in Patients With an Acute Gout Flare","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-04","primaryCompletion":"2007-10","completion":"2007-10","firstPosted":"2007-07-25","resultsPosted":"2009-09-22","lastUpdate":"2012-11-01"},"enrollment":185,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Gout"],"interventions":[{"type":"DRUG","name":"High Dose Colchicine (4.8 mg total dose)","otherNames":["Colcrys TM, Colchicine 0.6 mg"]},{"type":"DRUG","name":"Low Dose Colchicine (1.8mg total dose)","otherNames":["Colcrys TM, Colchicine 0.6 mg"]},{"type":"OTHER","name":"Placebo Control","otherNames":["Placebo capsule"]}],"arms":[{"label":"High Dose Colchicine","type":"EXPERIMENTAL"},{"label":"Low Dose Colchicine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is a multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-comparison to determine the efficacy and safety of a standard-dose of colchicine (4.8 mg) versus low-dose colchicine (1.8 mg) or placebo for acute gout flares.","primaryOutcome":{"measure":"Responders","timeFrame":"24 hours after baseline","effectByArm":[{"arm":"High Dose Colchicine(MPC-004)","deltaMin":17,"sd":null},{"arm":"Low Dose Colchicine(MPC-004)","deltaMin":28,"sd":null},{"arm":"Placebo","deltaMin":9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":83,"countries":["United States"]},"refs":{"pmids":["20131255"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":52},"commonTop":["Diarrhea","Nausea","Vomiting","Fatigue","Gout"]}}